AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of formula (I)



wherein:

R_1, R_2 and R_3, which can be the same or different, are OMe, NO_2, NHR';

X and Y are halogen or H with at least one of them being halogen;

Z = H or halogen

R = OH, OPO_3Na_2, $OCH_2OPO_3Na_2$, NO_2, NHR';

R' = H, alkyl (C_1-C_6);

~~R" = H, an amino acid side chain, Ph;~~

~~n an integer comprised between 1 and 3;~~

its pharmaceutically acceptable salt, racemate and single enantiomer.

2. (previously presented) A compound according to Claim 1, selected from the group consisting of:

a compound wherein at least one of X and Y is halogen, R_1-R_3 are methoxy, and R is hydroxy;

a compound wherein at least one of X and Y is halogen, R_1-R_3 are methoxy, R is amino or substituted amino;

a compound wherein at least one of X and Y is halogen, R_1-R_3 are different from methoxy, R is

hydroxy; and

a compound wherein R is OPO_3Na_2.

3. (canceled).

4. (previously presented) A compound according to Claim 1 selected from the group consisting of:

X = Y = F; R = OPO_3Na_2: difluorocombretastatin;

X = Y = F; R = NH_2: difluoroaminocombretastatin;

X = H; Y = F; R = OPO_3Na_2: monofluorocombretastatin;

X = F; Y = H; R = OPO_3Na_2: monofluorocombretastatin;

X = H; Y = F; R = NH_2: monofluoroaminocombretastatin;

X = F; Y = H; R = NH_2: monofluoroaminocombretastatin; and

X= Br; Y=F; R= OPO_3Na_2 bromofluorocombretastatin.

5. (original) A process for the preparation of the compounds of Claim 1, wherein X and Y are both F comprising the following steps:

a) reaction of 1-bromo-1,2-difluoro-2-(4-methoxy-3-(protected OH)-phenyl)ethene with 3-R_1-4-R_2-5-R_3-phenylboronic acid, and

b) restoring the 3-(protected OH) group.

6. (original) A process for the preparation of compounds of Claim 1, wherein one of the X and Y is F and the other one is hydrogen, comprises the following steps:

a) bromofluorination of the compound of Formula (I), wherein X and Y are H, and

b) base-promoted HBr elimination.

7. (original) A process for the preparation of compounds of Claim 1, wherein one of the X and Y is F, comprising the following steps:

a) transformation of compound of Formula (I), wherein X and Y are H into the respective bromohydrin, and

b) base-promoted HBr elimination.

8. (original) A process for the preparation of compounds of Claim 1, wherein one of the X and Y is F, comprising the following steps:

a) transformation of compound of Formula (I), wherein X and Y are H into the respective epoxide;

b) epoxide opening to give the respective bromohydrin, and

c) base-promoted HBr elimination, or in alternative,

d) epoxide opening to give the respective fluorohydrin, and

e) elimination of the opportune hydroxyl derivative.

9. (original) A process for the preparation of compounds of Claim 1, wherein one of the X or Y is F and the other is Br, comprising the following steps:

a) transformation of compound of Formula (I), wherein X and Y are H into the respective bromohydrin, and

b) base-promoted HBr elimination.

10. (previously presented) A method of inhibiting tubulin polymerization comprising administering to a subject an effective amount of a compound of claim 1.

11.-12. (canceled).

13. (canceled).

14. (previously presented) A method of treating a tumour selected from the group consisting of sarcoma, carcinoma, carcinoid, bone tumour, neuroendocrine tumour, lymphoid leukaemia, acute promyelocytic leukaemia, myeloid leukaemia, monocytic leukaemia, megakaryoblastic

leukaemia, non Hodgkin's disease, hemangiomas and multiple myeloma, and anaplastic thyroid cancer, comprising administering to a subject an effective amount of a compound of claim 1.

15. (canceled).

16. (canceled).

17. (previously presented) A method of treating a pathological state caused by abnormal angiogenesis selected from the group consisting of tumour metastases; arthritic disease; diabetic retinopathy; macular degeneration, psoriasis; chronic inflammatory diseases and arteriosclerosis comprising administering to a subject an effective amount of a compound of claim 1.

18. (canceled).

19. (previously presented) A pharmaceutical composition comprising at least a compound of Claim 1, in admixture with at least one pharmaceutically acceptable carrier and/or excipient.

20. (previously presented) A method of treating ischemia-induced proliferative retinopathy comprising administering to a subject an effective amount of a compound of claim 1.

21. (previously presented) A method of treating a lung carcinoma comprising administering to a subject an effective amount of a compound of claim 1.